Several studies have shown that simultaneously targeting multiple antioxidant systems (for instance both GSH and TXNR systems) can potentially provide better therapeutic outcomes and even synergistic combinatorial effects for cancer treatment in preclinical models [28–30]. The gene discussed is TXNRD1; the disease is cancer.